306 related articles for article (PubMed ID: 29344898)
1. Methods for High-throughput Drug Combination Screening and Synergy Scoring.
He L; Kulesskiy E; Saarela J; Turunen L; Wennerberg K; Aittokallio T; Tang J
Methods Mol Biol; 2018; 1711():351-398. PubMed ID: 29344898
[TBL] [Abstract][Full Text] [Related]
2. An integrated framework for identification of effective and synergistic anti-cancer drug combinations.
Sharma A; Rani R
J Bioinform Comput Biol; 2018 Oct; 16(5):1850017. PubMed ID: 30304987
[TBL] [Abstract][Full Text] [Related]
3. SNSynergy: Similarity network-based machine learning framework for synergy prediction towards new cell lines and new anticancer drug combinations.
Huangfu X; Zhang C; Li H; Li S; Li Y
Comput Biol Chem; 2024 Jun; 110():108054. PubMed ID: 38522389
[TBL] [Abstract][Full Text] [Related]
4. Unlocking the Potential of High-Throughput Drug Combination Assays Using Acoustic Dispensing.
Chan GK; Wilson S; Schmidt S; Moffat JG
J Lab Autom; 2016 Feb; 21(1):125-32. PubMed ID: 26160862
[TBL] [Abstract][Full Text] [Related]
5. Screening-based approach to discover effective platinum-based chemotherapies for cancers with poor prognosis.
Varbanov HP; Kuttler F; Banfi D; Turcatti G; Dyson PJ
PLoS One; 2019; 14(1):e0211268. PubMed ID: 30695050
[TBL] [Abstract][Full Text] [Related]
6. Research Techniques Made Simple: Preclinical Development of Combination Antitumor Targeted Therapies in Dermatology.
Yumeen S; Mirza FN; Lewis JM; Girardi M
J Invest Dermatol; 2020 Dec; 140(12):2319-2325.e1. PubMed ID: 33222758
[TBL] [Abstract][Full Text] [Related]
7. Drug combination sensitivity scoring facilitates the discovery of synergistic and efficacious drug combinations in cancer.
Malyutina A; Majumder MM; Wang W; Pessia A; Heckman CA; Tang J
PLoS Comput Biol; 2019 May; 15(5):e1006752. PubMed ID: 31107860
[TBL] [Abstract][Full Text] [Related]
8. Combinatorial drug screening identifies compensatory pathway interactions and adaptive resistance mechanisms.
Axelrod M; Gordon VL; Conaway M; Tarcsafalvi A; Neitzke DJ; Gioeli D; Weber MJ
Oncotarget; 2013 Apr; 4(4):622-35. PubMed ID: 23599172
[TBL] [Abstract][Full Text] [Related]
9. Identification of cisplatin sensitizers through high-throughput combinatorial screening.
Sun Y; Jiang W; Lu W; Song M; Liu K; Chen P; Chang A; Ling J; Chiao PJ; Hu Y; Huang P
Int J Oncol; 2018 Sep; 53(3):1237-1246. PubMed ID: 29956742
[TBL] [Abstract][Full Text] [Related]
10. Rapid identification and validation of novel targeted approaches for Glioblastoma: A combined ex vivo-in vivo pharmaco-omic model.
Daher A; de Groot J
Exp Neurol; 2018 Jan; 299(Pt B):281-288. PubMed ID: 28923369
[TBL] [Abstract][Full Text] [Related]
11. Biological insights into effective and antagonistic combinations of targeted agents with chemotherapy in solid tumors.
Ocaña A; Freedman O; Amir E; Seruga B; Pandiella A
Cancer Metastasis Rev; 2014 Mar; 33(1):295-307. PubMed ID: 24338003
[TBL] [Abstract][Full Text] [Related]
12. DrugCombDB: a comprehensive database of drug combinations toward the discovery of combinatorial therapy.
Liu H; Zhang W; Zou B; Wang J; Deng Y; Deng L
Nucleic Acids Res; 2020 Jan; 48(D1):D871-D881. PubMed ID: 31665429
[TBL] [Abstract][Full Text] [Related]
13. Identification of potential ibrutinib combinations in hematological malignancies using a combination high-throughput screen.
Schaffer M; Chaturvedi S; Davis C; Aquino R; Stepanchick E; Versele M; Liu Y; Yang J; Lu R; Balasubramanian S
Leuk Lymphoma; 2018 Apr; 59(4):931-940. PubMed ID: 28750570
[TBL] [Abstract][Full Text] [Related]
14. Mind the Curve: Dose-Response Fitting Biases the Synergy Scores across Software Used for Chemotherapy Combination Studies.
Fuentealba-Manosalva O; Mansilla M; Buelvas N; Martin-Martin A; Torres CG; López-Muñoz RA
Int J Mol Sci; 2023 Jun; 24(11):. PubMed ID: 37298656
[TBL] [Abstract][Full Text] [Related]
15. Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment.
Friedman AA; Amzallag A; Pruteanu-Malinici I; Baniya S; Cooper ZA; Piris A; Hargreaves L; Igras V; Frederick DT; Lawrence DP; Haber DA; Flaherty KT; Wargo JA; Ramaswamy S; Benes CH; Fisher DE
PLoS One; 2015; 10(10):e0140310. PubMed ID: 26461489
[TBL] [Abstract][Full Text] [Related]
16. A high-throughput drug combination screen of targeted small molecule inhibitors in cancer cell lines.
Flobak Å; Niederdorfer B; Nakstad VT; Thommesen L; Klinkenberg G; Lægreid A
Sci Data; 2019 Oct; 6(1):237. PubMed ID: 31664030
[TBL] [Abstract][Full Text] [Related]
17. An Unbiased Oncology Compound Screen to Identify Novel Combination Strategies.
O'Neil J; Benita Y; Feldman I; Chenard M; Roberts B; Liu Y; Li J; Kral A; Lejnine S; Loboda A; Arthur W; Cristescu R; Haines BB; Winter C; Zhang T; Bloecher A; Shumway SD
Mol Cancer Ther; 2016 Jun; 15(6):1155-62. PubMed ID: 26983881
[TBL] [Abstract][Full Text] [Related]
18. Applying synergy metrics to combination screening data: agreements, disagreements and pitfalls.
Vlot AHC; Aniceto N; Menden MP; Ulrich-Merzenich G; Bender A
Drug Discov Today; 2019 Dec; 24(12):2286-2298. PubMed ID: 31518641
[TBL] [Abstract][Full Text] [Related]
19. Real-Time Cell Migration Monitoring to Analyze Drug Synergism in the Scratch Assay Using the IncuCyte System.
Kobelt D; Walther W; Stein US
Methods Mol Biol; 2021; 2294():133-142. PubMed ID: 33742398
[TBL] [Abstract][Full Text] [Related]
20. Adenosine A2A receptor agonists and PDE inhibitors: a synergistic multitarget mechanism discovered through systematic combination screening in B-cell malignancies.
Rickles RJ; Pierce LT; Giordano TP; Tam WF; McMillin DW; Delmore J; Laubach JP; Borisy AA; Richardson PG; Lee MS
Blood; 2010 Jul; 116(4):593-602. PubMed ID: 20382846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
